american diabetes association pancreatitis glp-1 receptor agonist history Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Glucagon-Like Peptide-1 Receptor Agonists and
Description
During glucose regulation, activation of these receptors helps improve the function of -cells and protect the pancreas, enhancing insulin secretion and better controlling blood sugar levels

With aging, impairments in mitochondrial efficiency are associated with increased reactive oxygen species (ROS) production and declining bioenergetic capacity [10]
Several companies have GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists in phase 1 studies, including SCO-094 (Scohia Pharma), VK2735 (Viking Therapeutics) and CT-388 (Carmot Therapeutics)

However, some patients report better tolerability at equivalent weight loss levels, possibly due to the balancing effects of GIP

These treatments have helped people lose weight when diet and exercise havent been enough
